Executive Summary

**Purpose:** To control expenditures on expensive drug therapies by setting a day supply limitation for newly initiated oral oncology agents.

**Why Issue Selected:** Oral oncology agents are generally expensive, and many have serious side effects. The 15 Day Supply - Oral Oncology Fiscal Edit requires providers and participants to initiate these expensive medications that have serious side effects for a shorter amount of time; this allows the provider to confirm effectiveness and tolerability prior to MO HealthNet paying for a full 30-day supply, minimizing unnecessary expense, as well as medication waste. This program is for participants who are new starts to therapy only. Oral oncology agents with special packaging restrictions that require dispensing in the original container are excluded from this edit.

**Type of Criteria:**
- ☒ Increased risk of ADE
- ☐ Preferred Drug List
- ☐ Appropriate Indications
- ☒ Fiscal Edit

**Data Sources:**
- ☒ Only Administrative Databases
- ☐ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Oral Oncology Agents
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Claim has a usual and customary amount less than $150.00 OR
- Claim is for ≤ 15 day supply OR
- Documented history of therapy with an agent in the same HICL as the incoming claim in the past year

Denial Criteria

- Therapy will be denied if all approval criteria are not met
Required Documentation

<table>
<thead>
<tr>
<th>Laboratory Results:</th>
<th>Progress Notes:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

MedWatch Form: Other:

Disposition of Edit

Denial: Exception code “0712” (Exceed Initial Therapy Limitation)
Rule Type: PD

Default Approval Period

1 year